Kobayashi Pharmaceutical reported an “extraordinary loss” of nearly US$25m (JPY$3.86bn) in its Q1 results due to the recall of its contaminated red yeast rice products, raw materials, and compensation of medical expenses.
More than 110 health hazards involving 18 Foods with Function Claims (FFC) products were declared by FFC businesses over the past two weeks, Japan’s Consumer Affairs Agency (CAA) said.